Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for United Therapeutics (UTHR) over the last 11 years, with Q3 2025 value amounting to $48.1 million.

  • United Therapeutics' Shares Outstanding (Diluted Average) fell 82.47% to $48.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.1 million, marking a year-over-year decrease of 82.47%. This contributed to the annual value of $48.5 million for FY2024, which is 241.45% down from last year.
  • Per United Therapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $48.1 million for Q3 2025, which was down 82.47% from $48.5 million recorded in Q2 2025.
  • In the past 5 years, United Therapeutics' Shares Outstanding (Diluted Average) registered a high of $49.7 million during Q3 2023, and its lowest value of $46.4 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $48.5 million, with a median of $48.5 million in 2022.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 672.65% in 2021, then tumbled by 241.45% in 2024.
  • Over the past 5 years, United Therapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $47.3 million in 2021, then rose by 2.54% to $48.5 million in 2022, then increased by 2.47% to $49.7 million in 2023, then dropped by 2.41% to $48.5 million in 2024, then dropped by 0.82% to $48.1 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $48.1 million in Q3 2025, compared to $48.5 million in Q2 2025 and $48.6 million in Q1 2025.